Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Relx PLC Director's Dealing 2019

May 1, 2019

5248_dirs_2019-05-01_1c232485-21e6-4ec2-81cf-8495681a3ace.html

Director's Dealing

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7903X

RELX PLC

01 May 2019

ISSUED ON BEHALF OF RELX PLC

Director/PDMR Shareholdings

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Henry Udow
2 Reason for the notification
a) Position/status PDMR
b) Initial notification /Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name RELX PLC
b) LEI 549300WSX3VBUFFJOO66
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 14 51/116p each ('Ordinary Shares')
Identification code ISIN: GB00B2B0DG97
b) Nature of the transaction Exercise of an option over Ordinary Shares under the RELX Group plc Executive Share Option Scheme 2003. The option price payable on exercise was £5.39 per share.
c) Price(s) and volume(s)
Price(s) Volume(s)
£5.39 25,831
d) Aggregated information
- Aggregated volume 25,831
- Price £5.39
e) Date of the transaction 2019-04-29
f) Place of the transaction Outside of a trading venue
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 14 51/116p each ('Ordinary Shares')
Identification code ISIN: GB00B2B0DG97
b) Nature of the transaction Sale of Ordinary Shares
c) Price(s) and volume(s)
Price(s) Volume(s)
£17.590000 50,831
d) Aggregated information
- Aggregated volume 50,831
- Price £17.590000
e) Date of the transaction 2019-04-29
f) Place of the transaction London Stock Exchange (XLON)
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 14 51/116p each ('Ordinary Shares')
Identification code ISIN: GB00B2B0DG97
b) Nature of the transaction Exercise of an option over Ordinary Shares under the RELX Group plc Executive Share Option Scheme 2003. The option price payable on exercise was €5.832 per share.
c) Price(s) and volume(s)
Price(s) Volume(s)
€5.832 26,538
d) Aggregated information
- Aggregated volume 26,538
- Price €5.832
e) Date of the transaction 2019-04-29
f) Place of the transaction Outside of a trading venue
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 14 51/116p each ('Ordinary Shares')
Identification code ISIN: GB00B2B0DG97
b) Nature of the transaction Sale of Ordinary Shares
c) Price(s) and volume(s)
Price(s) Volume(s)
€20.395000 51,538
d) Aggregated information
- Aggregated volume 51,538
- Price €20.395000
e) Date of the transaction 2019-04-29
f) Place of the transaction Euronext Amsterdam Stock Exchange (XAMS)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHLLFISERILIIA